APTO(Delisted)
Aptose Biosciences·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APTO
Aptose Biosciences Inc.
A clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies
251 Consumers Road, Suite 1105, Toronto, Ontario, Canada M2J 4R3
--
Aptose Biosciences Inc., was incorporated on September 5, 1986 under the Business Companies Act as RML Medical Laboratories Inc. On September 2, 2014, the company changed its name to Aptose Biosciences Inc.. Aptose Biosciences Inc. is a science-oriented clinical-stage biotechnology company dedicated to precision medicine to meet the unmet clinical needs of oncology, with an initial focus on hematology. The company's small molecule cancer treatment product line includes products designed to provide single drug efficacy and enhance the efficacy of other anticancer therapies and regimens without overlapping toxicity.
Company Financials
EPS
APTO has released its 2025 Q2 earnings. EPS was reported at -2.76, versus the expected -2.45, missing expectations. The chart below visualizes how APTO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
